Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 12
Submit an article Journal homepage
144
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

Insurance-based disparities impact survival outcomes in Waldenström macroglobulinemia within the United States

Karan L. Chohana Department of Medicine, Mayo Clinic, Rochester, MN, USA
,
Jithma P. Abeykoonb Division of Hematology, Mayo Clinic, Rochester, MN, USAORCID Iconhttps://orcid.org/0000-0003-3939-6252
ORCID Icon,
Stephen M. Ansellb Division of Hematology, Mayo Clinic, Rochester, MN, USA
,
Morie A. Gertzb Division of Hematology, Mayo Clinic, Rochester, MN, USAORCID Iconhttps://orcid.org/0000-0002-3853-5196
ORCID Icon,
Prashant Kapoorb Division of Hematology, Mayo Clinic, Rochester, MN, USA
,
Aneel Paulusc Division of Hematology, Mayo Clinic, Jacksonville, FL, USAORCID Iconhttps://orcid.org/0000-0001-8765-9649
ORCID Icon,
Sikander Ailawadhic Division of Hematology, Mayo Clinic, Jacksonville, FL, USAORCID Iconhttps://orcid.org/0000-0002-8377-8111
ORCID Icon,
Craig B. Reederd Division of Hematology, Mayo Clinic, Phoenix, AZ, USA
,
Thomas E. Witzigb Division of Hematology, Mayo Clinic, Rochester, MN, USAORCID Iconhttps://orcid.org/0000-0002-4215-6500
ORCID Icon,
Thomas M. Habermannb Division of Hematology, Mayo Clinic, Rochester, MN, USA
,
Martha Q. Lacyb Division of Hematology, Mayo Clinic, Rochester, MN, USA
,
Robert A. Kyleb Division of Hematology, Mayo Clinic, Rochester, MN, USA
,
Ronald S. Gob Division of Hematology, Mayo Clinic, Rochester, MN, USAORCID Iconhttps://orcid.org/0000-0002-8284-3495
ORCID Icon &
Jonas Paludob Division of Hematology, Mayo Clinic, Rochester, MN, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7350-5531
ORCID Icon show all
Pages 2879-2888 | Received 31 May 2022, Accepted 11 Jul 2022, Published online: 23 Jul 2022

References

  • Gertz MA. Waldenstrom macroglobulinemia: 2019 update on diagnosis, risk stratification, and management. Am J Hematol. 2019;94(2):266–276.
  • Yun S, Johnson AC, Okolo ON, et al. Waldenstrom macroglobulinemia: review of pathogenesis and management. Clin Lymphoma Myeloma Leuk. 2017;17(5):252–262.
  • Kastritis E, Morel P, Duhamel A, et al. A revised international prognostic score system for Waldenstrom's macroglobulinemia. Leukemia. 2019;33(11):2654–2661.
  • Unger JM, Moseley AB, Cheung CK, et al. Persistent disparity: socioeconomic deprivation and cancer outcomes in patients treated in clinical trials. J Clin Oncol. 2021;39(12):1339–1348.
  • Singh GK, Jemal A. Socioeconomic and racial/ethnic disparities in cancer mortality, incidence, and survival in the United States, 1950-2014: over six decades of changing patterns and widening inequalities. J Environ Public Health. 2017;2017:2819372.
  • Ailawadhi S, Kardosh A, Yang D, et al. Outcome disparities among ethnic subgroups of Waldenstrom's macroglobulinemia: a population-based study. Oncology. 2014;86(5–6):253–262.
  • Gunaratne M, Sahakian AJ, Abeykoon JP, et al. Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia. Leuk Lymphoma. 2021;62(2):308–315.
  • Niu X, Roche LM, Pawlish KS, et al. Cancer survival disparities by health insurance status. Cancer Med. 2013;2(3):403–411.
  • Goldstein JS, Nastoupil LJ, Han X, et al. Disparities in survival by insurance status in follicular lymphoma. Blood. 2018;132(11):1159–1166.
  • Parikh RR, Grossbard ML, Green BL, et al. Disparities in survival by insurance status in patients with Hodgkin lymphoma. Cancer. 2015;121(19):3515–3524.
  • Halpern MT, Ward EM, Pavluck AL, et al. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. Lancet Oncol. 2008;9(3):222–231.
  • Yang K, Castillo JJ, Ratiu A, et al. Real-world treatment patterns, adherence, costs, and healthcare resource utilization associated with Waldenström macroglobulinemia in the United States. J Clin Oncol. 2021;39(15_suppl):e18766–e18766.
  • (NCDB) NCD. Participant User Files. 2022.
  • Surgeons ACo. National Cancer Database. 2022.
  • HHS. Medicare and Medicaid. 2022.
  • Goldstein JS, Switchenko JM, Behera M, et al. Insurance status impacts overall survival in Burkitt lymphoma. Leuk Lymphoma. 2019;60(13):3225–3234.
  • Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
  • Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682.
  • Bureau USC. American Community Survey Data. 2016.
  • Perry AM, Brunner AM, Zou T, et al. Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: a population-based study. Cancer. 2017;123(13):2561–2569.
  • Makhani SS, Shively D, Castro G, et al. Association of insurance disparities and survival in adults with multiple myeloma: a non-concurrent cohort study. Leuk Res. 2021;104:106542.
  • Ambroggi M, Biasini C, Del Giovane C, et al. Distance as a barrier to cancer diagnosis and treatment: review of the literature. Oncologist. 2015;20(12):1378–1385.
  • Treon SP. How I treat Waldenström macroglobulinemia. Blood. 2015;126(6):721–732.
  • Dimopoulos MA, Kastritis E. How I treat Waldenström macroglobulinemia. Blood. 2019;134(23):2022–2035.
  • Mohammadi M, Cao Y, Glimelius I, et al. The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma – a Swedish population-based study. BMC Cancer. 2015;15(1):850.
  • Lee YK, Hong N, Park SH, et al. The relationship of comorbidities to mortality and cause of death in patients with differentiated thyroid carcinoma. Sci Rep. 2019; 9(1):11435.
  • Jain V, Venigalla S, Sebro RA, et al. Association of health insurance status with presentation, treatment and outcomes in soft tissue sarcoma. Cancer Med. 2019;8(14):6295–6304.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.